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 ABSTRACT  
 Objectives  In chronic infl ammatory disorders, 
interleukin (IL)-22 may act either as a protective or as 
a pro-infl ammatory cytokine. At mucosal sites, IL-22 
is mainly produced by CD4 + T cells and by a subset of 
mucosal natural killer (NK) cells expressing the receptor 
NKp44 (NKp44 + NK cells). The aim of this study was to 
investigate the IL-22 expression in the salivary glands of 
patients with primary Sjögren’s syndrome (pSS). 
 Methods  Minor salivary gland biopsies were obtained 
from 19 patients with pSS and 16 with non-specifi c 
chronic sialoadenitis. Quantitative gene expression analysis 
by TaqMan real-time PCR and immunohistochemistry 
for IL-17, IL-22, IL-23 and STAT3 (signal transducer and 
activator of transcription) was performed on salivary 
glands from patients and controls. The cellular sources 
of IL-22 among infi ltrating infl ammatory cells were also 
determined by fl uorescence-activated cell sorting analysis 
and immunohistochemistry. 
 Results  IL-22, IL-23 and IL-17 were signifi cantly 
increased at both protein and mRNA levels in the 
infl amed salivary glands of patients with pSS. STAT3 
mRNA and the tyrosine phosphorylated corresponding 
protein were also signifi cantly increased in pSS. Th17 
and NKp44 + NK cells were the major cellular sources 
of IL-22 in patients with pSS. 
 Conclusions  Our results suggest that, together with 
IL-17 and IL-23, IL-22 may play a pro-infl ammatory role 
in the pathogenesis of pSS. 
 INTRODUCTION 
 Primary Sjögren’s syndrome (pSS) is a chronic sys-
temic autoimmune disease associated with vari-
able degrees of lymphocytic infi ltration of salivary 
and lacrimal glands leading to xerostomia and 
xerophthalmia. 1 
 The mechanisms initiating or maintaining the 
chronic and persistent immunological activation 
involved in the pathogenesis of SS are poorly 
understood. 
 Several cytokines and chemokines are increased 
in the peripheral blood and in the infl amed salivary 
glands. 2  3 A major contribution of B cells in the 
pathophysiology of pSS through the production of 
autoantibodies and cytokines 4 – 6 and the constitu-
tion of germinal centres in the salivary glands has 
been demonstrated. 7 In addition to B lymphocytes, 
T lymphocytes are also involved in the local 
immune response observed in patients with pSS, 
mainly through the activation of the Th1 and Th17 
pathways. 8 – 10 The presence of Th1- and Th17-
related cytokines has been in fact demonstrated 
in salivary glands from patients with pSS in terms 
of mRNA and protein expression. 8 – 10 Interestingly, 
both Th1 and Th17 cells express interleukin (IL)-22 
that is known to play a role in the pathogenesis of 
T cell-mediated infl ammatory disorders. 11 
 IL-22, a member of the IL-10 cytokine family, 
is well known as a key player in immune surveil-
lance, infl ammation and tissue homeostasis. 12  13 At 
mucosal sites, IL-22 is mainly produced by CD4 + 
T cells and by a subset of mucosal natural killer 
(NK) cells expressing the receptor NKp44 (namely, 
NKp44 + NK cells). 14 In chronic infl ammatory dis-
orders, IL-22 may act either as a protective or as 
a pro-infl ammatory cytokine depending on the 
coexpression of IL-17. 15 Interestingly, high levels of 
IL-22, directly correlated with hyposalivation, anti-
SSA and/or anti-SSB, hypergammaglobulinaemia 
and rheumatoid factor, have been recently demon-
strated in the sera of patients with pSS, suggesting 
a critical direct role of IL-22 in the development of 
SS. 16 
 Whether IL-22 and IL-22-producing cells may be 
implicated in the local immune response observed 
in the salivary glands of patients with SS is how-
ever still unknown. 
 The purpose of the present study was to inves-
tigate the IL-22 expression and the IL-22 cellular 
sources in infl amed salivary glands of patients with 
pSS. Since IL-22 is a downstream effector cytokine 
of IL-23 and the fi nal outcome of IL-22 seems to 
be determined by the coexpression of IL-17, 15 we 
also evaluated the expression of IL-23 and IL-17. 
Finally, since studies investigating IL-22-induced sig-
nal transduction in cells with endogenous receptor 
expression demonstrated tyrosine phosphorylation 
of signal transducer and activator of transcription 
(STAT3), 17 we also evaluated the expression of 
phosphorylated STAT3 (p-STAT3). 
 MATERIALS AND METHODS 
 Patients 
 Thirty-fi ve patients with subjective complaints of 
dry mouth or dry eyes who were referred to our uni-
versity hospital outpatient clinic were considered 
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for this study. Nineteen patients met the American–European 
Consensus Group criteria for pSS. 18 The remaining 16 patients 
were classifi ed as having non-specifi c chronic sialoadenitis (nSS). 
Minor salivary gland biopsies from the last patients showed 
various degrees of mononuclear cell infi ltration in the absence 
of focal organisation and did not fulfi l the American–European 
Consensus Group criteria for SS. The presence of other underly-
ing autoimmune diseases or hepatitis C virus infection was care-
fully excluded. All patients and controls underwent serological 
evaluations, which included tests for the presence of antinuclear 
antibodies, anti-SSA/Ro, anti-SSB/La, rheumatoid factor, levels 
of C reactive protein and erythrocyte sedimentation rate. An 
unstimulated whole sialometry was also performed. The char-
acteristics of patients and controls are shown in  table 1 . 
 Labial salivary gland biopsy 
 Up to 10 labial salivary gland biopsies were obtained, after 
obtaining informed consent, during routine diagnostic proce-
dures. Of these biopsies, four were embedded in paraffi n and 
used for histopathological analysis and immunohistochemistry 
(IHC), two were used for mRNA isolation and real-time (RT)-
PCR analysis. When available, the remaining biopsies were 
placed into Dulbecco’s modifi ed Eagle’s medium for cell isola-
tion and fl uorescence-activated cell sorting analysis. 
 Histological evaluation 
 Standard paraffi n sections at 5 μm thickness were stained with 
H&E. Histological evaluation of salivary glands for the presence 
of lymphocytic infi ltrates and/or foci was performed according 
to Greenspan and coworkers. 19 A focus was defi ned as an aggre-
gate of ≥50 lymphocytes. The focus score was reported as the 
number of foci per 4 mm 2 of tissue, up to a maximum of 12 
foci. All patients with pSS presented a biopsy focus score >1, 
whereas the control group had a focus score <1. On the basis 
of the histological evaluation, we identifi ed in patients with pSS 
a median biopsy focus score of 5.37 (range 2–11), while no foci 
were observed in patients with nSS. 
 RNA isolation and quantitative RT-PCR 
 Salivary gland biopsies soon after removal were stored in 
RNAlater solution (Applied Biosystems, Foster City, California, 
USA). Each sample was lysed in a tissue homogeniser, and 
RNA was extracted using the commercially available illustra 
RNAspin Mini Isolation Kit (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK), according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed to cDNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Samples were stored at −20°C until use. For quantitative TaqMan 
RT-PCR, master mix and TaqMan gene expression assays for 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) control 
for IL-17 (Hs00174383_m1), IL-22 (Hs01574154_m1), IL-23 
(Hs00372324_m1) and STAT3 (Hs00234174_m1) were obtained 
from Applied Biosystems. Samples were run in triplicate using 
the Step-One RT-PCR System (Applied Biosystems). Relative 
changes in gene expression between nSS and pSS samples were 
determined using the ∆∆C t method. Levels of the target transcript 
were normalised to a GAPDH endogenous control, constantly 
expressed in both groups (∆C t ). For ∆∆C t values, additional sub-
tractions were performed between pSS samples and nSS ∆C t 
values. Final values were expressed as fold of induction. 
 Immunohistochemical staining for IL-17, IL-22, IL-23, p-STAT3 
and NKp44 
 Tissue samples were immediately fi xed with 4% formaldehyde 
and embedded in paraffi n. IHC for IL-17, IL-22, IL-23, p-STAT3 
and NKp44 was performed on 5-μm-thick paraffi n-embedded 
sections from salivary glands and from tonsils and lymph node 
(used as positive controls) as previously described. 20 Isotype-
matched irrelevant antibodies were used as a negative control. 
Briefl y, following rehydration, antigen was unmasked for 45 min 
in a 95°C microwave using Dako Target Retrieval Solution 
(pH 6; Dako, Carpinteria, California, USA). Endogenous per-
oxidase was blocked for 10 min with Dako peroxidase blocking 
reagent, and non-specifi c binding was blocked for 20 min with 
Dako protein block. The primary antibodies rabbit antihuman 
IL-17 (IgG, sc7927, 1:100 dilution) (Santa Cruz Biotechnology, 
Santa Cruz, California, USA), rabbit antihuman IL-22 
(IgG, NB100–737, 1:100 dilution) (Novus Biologicals, Littleton, 
Colorado, USA), mouse antihuman IL-23p19 (IgG1, HLT2736, 
1:50 dilution) (BioLegend, San Diego, California, USA), rabbit 
antihuman pSTAT-3 (Tyr705) (IgG, D3A7, 1:50 dilution) (Cell 
Signaling Technology, Beverly, Massachusetts, USA) and anti-
human NKp44 (Mouse IgG1, P44-8, 1:100 dilution) (BioLegend) 
were added and incubated for 1 h at room temperature. For con-
trol staining, primary antibodies were replaced with irrelevant 
isotype-matched antibodies (AbCam, Cambridge, UK). Then, 
the slides were incubated for 30 min with peroxidase-conju-
gated Dako EnVision polymer, and peroxidase activity was visu-
alised using diaminobenzidine chromogen (Dako). Slides were 
lightly counterstained with haematoxylin before dehydration 
and mounting in DePex (VWR International, Oslo, Norway). 
Quantifi cation of IL-22-expressing cells was assessed by two 
independent investigators (FC and AR) by manually counting the 
positive cells on photomicrographs obtained from three random 
high-power microscopic fi elds (original magnifi cation, 400×) 
under a Leica DM2000 optical microscope using a Leica DFC320 
digital camera. Among infi ltrating cells, the number of positive 
cells was expressed as the percentage of IL-22-expressing cells. 
Ductal and/or acinar IL-22 expression was also graded accord-
ing to the following criteria: no IL-22 expression, grade 0; IL-22-
positive ductal cells <50%, grade 1; IL-22-positive ductal cells 
>50%, grade 2. Results were reported as the mean±SEM. 
 Flow cytometry 
 Salivary gland tissues were extensively washed in saline buf-
fer, and enzymatic digestion was performed using collagenase 
(1.5 mg/ml; Life Technologies, Carlsbad, California, USA) in 
Dulbecco’s modifi ed Eagle’s medium containing antibiotics for 
2 h. The recovered cells, including epithelial cells, were then cul-
tured with phorbol myristate acetate (50 ng/ml) and ionomycin 
 Table 1 Baseline characteristics of patients and controls 
  pSS (n=19)  nSS (n=16)  p Value 
Age (years (range)) 58 (31–70) 62 (28–76) NS
Female sex (n (%)) 16 (84) 12 (75) NS
Disease duration (months (range)) 80.8 (4–280) 77 (6–320) NS
Antinuclear antibodies (number of 
positive patients)
16  2 <0.001
Anti-SSA and/or anti-SSB antibodies 
(number of positive patients)
12  1 <0.001
Rheumatoid factor (number of positive 
patients)
11  1 –
ESR (mm/h (mean (SD))) 40 (13) 11.8 (6) <0.001
C reactive protein (mg/l (mean (SD))) 16.6 (6)  9 (3) <0.05
 ESR, erythrocyte sedimentation rate; nSS, non-specifi c chronic sialoadenitis; pSS, 
primary Sjögren’s syndrome. 
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Figure 1 IL-22 expression in salivary glands of patients with pSS. (A) Relative expression of IL-22 mRNA in whole minor salivary glands of patients 
with pSS. Data are normalised for GAPDH and plotted as fold of induction over minor salivary glands obtained from patients with nSS. Results represent 
the mean±SEM. Representative immunostainings for IL-22 in nSS (B) compared with patients with pSS with different grades of infl ammation (C,D). 
Signifi cant staining of IL-22 was observed only in patients with pSS (n=19) compared with patients with nSS (n=16). Positive stained cells were 
observed among infi ltrating mononuclear cells and ductal epithelial cells (C,D). (E) IL-22+ cells were considered as the percentage of the infi ltrating 
mononuclear cells. Correlation of IL-22+ mononuclear cells with focus scores. IL-22 expression by IHC was correlated with the focus score of minor 
salivary glands of pSS. The r (r=0.68) and p (p<0.0001) values were determined with Pearson’s correlation coeffi cient. (F) Ductal IL-22 expression was 
shown by the grading scale, and IL-22 expression of ductal cells correlated with focus scores. The r (r=0.80) and p (p<0.0001) values were determined 
with Pearson’s correlation coeffi cient. (B) Original magnifi cation, 100×. (C,D) Original magnifi cation, 400×. GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; IHC, immunohistochemistry; IL, interleukin; nSS, non-specifi c chronic sialoadenitis; pSS, primary Sjögren’s syndrome.
Figure 2 p-STAT3 expression in salivary glands of patients with pSS. Relative expression of STAT3 at the mRNA level (A) and of p-STAT3 at the protein 
level (B–D) in whole minor salivary glands of patients with pSS, controls and lymph node (E,F). Immune staining of p-STAT3 was almost exclusively 
observed in the infl amed salivary glands of pSS (B–D). Infi ltrating infl ammatory cells, high endothelial cells (asterisk) and ductal (arrows) and acinar (arrows) 
epithelial cells showed intense p-STAT3 positivity (D). In the context of lymph node, immune staining of p-STAT3 was observed in lymphocytes (E) and high 
endothelial cells (F) (asterisk). (A) Bars represent the mean±SEM. (B,C and E) Original magnifi cation, 100×. (D,F) Original magnifi cation, 250×. STAT3, 
signal transducer and activator of transcription; pSS, primary Sjögren’s syndrome; p-STAT3, phosphorylated signal transducer and activator of transcription.
(0.5 μg/ml) and incubated at 37°C in 5% CO 2 . Numbers of 
recovered cells were consistent with visual counts. After 2 h of 
incubation, Brefeldin A (10 μg/ml; Sigma, St. Louis, Missouri, 
USA) was added, and after 16 h of incubation, cells were col-
lected and stained with the following monoclonal antibodies: 
antihuman CD3-APC (BD Biosciences, San Jose, California, 
USA), antihuman CD56-PerCP-Cy5.5 (BioLegend), antihuman 
NKp44-PE (BioLegend), antihuman IL-22-FITC (R&D Systems, 
Minneapolis, Minnesota, USA), antihuman IFNγ-PE (BD 
Biosciences), antihuman IL-17-APC (R&D Systems), antihuman 
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CD4-PE-Cy5.5 (BD Biosciences) and an antihuman cytokeratin 
(clone MNF116; Dako, Glostrup, Denmark). Isotype-matched 
irrelevant antibodies were used as a negative control. Total cells 
were incubated with monoclonal antibodies for 30 min on ice 
and washed twice in phosphate-buffered saline, containing 
0.1% (w/v) NaN3. After surface staining, the cells were fi xed 
with 1% (w/v) paraformaldehyde (Sigma) for 30 min at 4°C and 
then were permeabilised with a permeabilisation solution (BD 
Biosciences) for 10 min at room temperature and stained with 
antibodies to intracellular antigens for 30 min at 4°C. Four-colour 
fl ow cytometry analysis was performed using a FACSCalibur 
(BD Biosciences). At least 5000 cells (events), gated on lympho-
cytes region, were acquired for each sample. 
 Statistical analysis 
 Statistical analysis of quantitative variables was performed 
using the Mann–Whitney rank-sum test. A χ 2 test with Yates’ 
correction when required was used to evaluate associations of 
qualitative variables in the different groups. Pearson’s correla-
tion analysis was used to quantify the expression associations 
between the genes of interest. p Values less than 0.05 were con-
sidered statistically signifi cant. 
 RESULTS 
 IL-22 expression in the salivary glands of patients with pSS 
 Previous studies have described the expression of various cytokines 
in patients with pSS (eg, IL-18, IL-7, IL-17 and IL-23); 10  15  21  22 how-
ever, there are no data on the expression of IL-22 in salivary glands. 
Minor labial salivary glands were evaluated for IL-22 expression 
at both mRNA and protein levels to determine whether this cytokine 
is part of the infl ammatory response in patients with pSS. 
 Signifi cantly higher levels of IL-22 mRNA were found in 
patients with pSS when compared with those of patients with 
nSS (9.25±1.32 vs 0.87±0.08, p<0.0001) ( fi gure 1A ) with a posi-
tive strong correlation between the IL-22 mRNA levels and the 
focus score (online supplementary fi gure 1). 
 Low levels of IL-22 expression were detected by IHC in all 
patients with chronic sialoadenitis ( fi gure 1B ). In pSS, the stain-
ing appeared localised to lymphocytic infi ltrates and ductal epi-
thelial cells. The typical distribution of IL-22 in pSS is shown in 
 fi gure 1C , D . The relative percentage of positively stained infi l-
trating mononuclear cells was correlated with the focus score 
(r=0.68, p<0.0001) ( fi gure 1E ). Ductal epithelial cells were also 
positive for IL-22 in pSS only, and the degree of IL-22 expression 
was correlated with the grade of infl ammation of the salivary 
Figure 3 Percentage of IL-22-producing cells in salivary glands with pSS. Freshly isolated SGMCs from six patients with pSS and six patients 
with nSS were stained with CD4-PE-Cy5.5, IFNγ-PE, IL-17-APC and IL-22-FITC and analysed by fl ow cytometry. (A) Representative dot plot analysis 
(left panel) of CD4 versus IL-22 among isolated SGMCs and percentages (right panel) of IL-22+ cells among CD4+ T lymphocytes in SGMCs of 
pSS and nSS. (B) Percentages of IL-22-positive cells among CD4+IFNγ+IL-17− Th1 lymphocytes. (C) Percentages of IL-22-positive cells among 
CD4+IFNγ−IL-17− Th22 lymphocytes in SGMCs of pSS and nSS. (D) Representative dot plot analysis of IL-17 versus IL-22 among isolated SGMCs 
(left panel) and percentages (right panel) of IL-22-positive cells among CD4+IFNγ−IL-17+Th17 lymphocytes in SGMCs of pSS and nSS. Bars show 
the mean and SEM. IL, interleukin; nSS, non-specifi c chronic sialoadenitis; pSS, primary Sjögren’s syndrome; SGMC, salivary gland mononuclear cell.
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glands ( fi gure 1F ). No evidence of IL-22 staining was detected in 
acinar epithelial cells, myoepithelial cells or fi broblasts. 
 IL-23, IL-17 and p-STAT3 expression in salivary glands of 
patients with pSS 
 Since IL-22 is a downstream effector cytokine of IL-23, 23  24 
we next evaluated the expression of IL-23. IL-23 mRNA was 
signifi cantly increased in patients with pSS but not in patients 
with nSS (2.72±0.4 vs 0.92±0.1, p=0.0002) (online supplemen-
tary fi gure 2A). Immunohistochemical analysis in all infl amed 
specimens of patients with pSS confi rmed the high expression 
of IL-23 at the protein level, the intensity of which was particu-
larly increased in those patients displaying a higher focus score 
(online supplementary fi gure 2B). 
 Because the functional outcome of IL-22 (whether protective 
or pro-infl ammatory) seems to be dependent on the coexpres-
sion of IL-17, 15 we next evaluated IL-17 expression levels. IL-17 
was increased at both mRNA (6.75±1.62 vs 0.9±0.07, p<0.0001) 
(online supplementary fi gure 2C) and protein (online supple-
mentary fi gure 2D) levels in patients with pSS and correlated 
with the degree of tissue infl ammation. 
 Both IL-23 and IL-22 signal through STAT3 in different cellular 
targets, mainly in lymphoid cells in the former and in the epithe-
lial cells in the latter. To assess whether IL-22 and IL-23 signals 
were active, we looked for the activation of its downstream signal 
pathway evaluating STAT3 mRNA and p-STAT3 protein expres-
sion. STAT3 mRNA expression was demonstrable in both patients 
with pSS and those with nSS, being signifi cantly increased in pSS 
(1.48±0.09 vs 0.96±0.05, p<0.01) ( fi gure 2A ). Since the activation of 
STAT molecules is indicated by their phosphorylated 25 status, we 
next analysed intracellular p-STAT3. Immune staining of p-STAT3 
was observed almost exclusively in the infl amed salivary glands 
of patients with pSS ( fi gure 2B , D ). As shown in  fi gure 2D , t hree 
patterns of positivity were observed. The fi rst pattern was char-
acterised by a large number of p-STAT3-producing cells, presum-
ably dendritic cells, distributed within the lymphomonocytic 
infl ammatory infi ltrate in the context of ductal epithelium. The 
second pattern, mainly epithelial, was characterised by a strong 
positivity in both acinar and ductal epithelial cells. The third pat-
tern was characterised by the p-STAT3 expression among high 
endothelial cells. Expression of p-STAT3 in endothelial cells and 
lymphocytes was also confi rmed in lymph node sections used as 
positive controls ( fi gure 2E , F ). 
 Identifi cation of IL-22-producing cells in salivary glands 
 The expression of IL-22 in the different infi ltrating populations 
was analysed by fl uorescence-activated cell sorting analysis on 
cells isolated from the minor salivary glands of patients with 
pSS and those with nSS. To date, the best characterised human 
mucosal cells that secrete IL-22 are CD4 + IL-22-expressing 
T cells (Th1, Th17 and Th22) and NKp44 + NK cells. 14 As shown 
in  fi gure 3A , I L-22-producing CD4 + T cells from patients with 
pSS were signifi cantly expanded compared to nSS (10.5±0.65 
vs 6.5±0.3, p<0.05). Among CD4 + T cells, the percentage of 
IL-22-producing Th1 (4.2±0.51 vs 2.84±0.4, p=NS) ( fi gure 3B ) 
and Th22 (1.36±0.06 vs 1.1±0.05, p=NS) ( fi gure 3C ) cells was 
not signifi cantly different when the two groups were com-
pared. Conversely, IL-22-producing Th17 cells (5.5±0.23 vs 
3.44±0.3, p<0.05) were signifi cantly expanded in patients with 
pSS ( fi gure 3D ). IL-22 production was also observed among epi-
thelial cells, with patients with pSS displaying a signifi cantly 
higher IL-22 expression than the controls (11.2% and 5.8%, 
respectively, p<0.05) ( fi gure 4A , B ). 
 NKp44 + NK cells are expanded and produce high levels of IL-22 
in salivary glands of pSS 
 At mucosal sites, IL-22 is also produced by a subset of mucosa-
associated NK cells that expresses the receptor NKp44 (namely, 
NKp44 + NK cells). 26 We investigated the IL-22 production by 
NK cells isolated from the salivary glands of patients with pSS 
and those with nSS. A signifi cantly increased proportion of NK 
cells was observed in patients with pSS compared with those 
with nSS (3.4±0.35 vs 1.8±1.3, p<0.05) ( fi gure 5A ). Among NK 
cells, CD3 − CD56 + NKp44 + NK cells were signifi cantly expanded 
(2±0.17 vs 0.958±0.045, p<0.05) and produced higher amounts of 
IL-22 in patients with pSS when compared to patients with nSS 
(0.914±0.07 vs 0.228±0.043, p<0.05) ( fi gure 5B , C ). The percentage 
of NKp44 + NK cells was directly and strongly correlated with the 
severity of tissue infl ammation in patients with pSS ( fi gure 5D ). 
Immunohistochemical analysis of salivary gland sections from 
pSS with anti-NKp44 antibody shows that NKp44 + NK cells reside 
within the infl ammatory infi ltrate of pSS ( fi gure 5E , F ). 
Figure 4 IL-22 expression in salivary gland epithelial cells of patients with pSS. (A) Representative dot plot analysis of cytokeratin (MF116) versus 
IL-22 among isolated salivary gland mononuclear cells. (B) Percentages of IL-22-positive cells among salivary gland epithelial cells. Bars show the 
mean and SEM. IL, interleukin; pSS, primary Sjögren’s syndrome.
23_annrheumdis-2011-154013.indd   299 12/23/2011   12:55:37 PM
group.bmj.com on November 14, 2016 - Published by http://ard.bmj.com/Downloaded from 
Basic and translational research
Ann Rheum Dis 2012;71:295–301. doi:10.1136/ard.2011.154013300
 DISCUSSION 
 In this study, we confi rm the increased expression of Th17-
related cytokines, IL-17 and IL-23, 8  10  11 and demonstrate, for 
the fi rst time, that IL-22 is overexpressed at both mRNA and 
protein levels in the infl amed salivary glands of pSS. Finally, we 
also provide evidence that Th17 cells and NKp44 + NK cells are 
the major sources of IL-22 in salivary glands. 
 IL-22 is a member of the IL-10 cytokine family and plays critical 
roles in infl ammation, immune surveillance and tissue homeosta-
sis at mucosal sites. 14 In autoimmune diseases, however, diverse 
tissue cytokine milieu and different pathogenic mechanisms may 
result in opposing roles of IL-22 in disease pathogenesis. 15 The 
pro-infl ammatory versus tissue-protective functions of IL-22 seem 
to be regulated by the coexpression of IL-17. 15 When coexpressed, 
IL-17 and IL-22 synergistically promote infl ammation through 
chemokine expression and neutrophil recruitment; on the other 
hand, IL-22 alone seems to act as a protective cytokine. 15  27 – 30 Our 
demonstration of concomitant IL-22 and IL-17 expression seems 
to suggest that in infl amed salivary glands of patients with pSS, 
IL-22 should play a predominant pro-infl ammatory role. 
 IL-22 should be considered as a downstream effector cytokine 
of IL-23. 23  24 In our pSS samples, both IL-22 and IL-23 were 
signifi cantly increased in pSS, supporting the existence of a func-
tionally relevant IL-23/IL-22 axis in the infl amed salivary glands 
of patients with pSS. 
 By IHC, we demonstrated a strong IL-22 positivity in the mono-
nuclear cells infi ltrating the infl amed salivary glands and in duc-
tal epithelial cells of patients with pSS, both correlated with the 
degree of tissue infl ammation. Epithelial cells are thought to play 
an important pathogenetic role in pSS, as suggested by the demon-
stration that, in the histopathological lesions of patients with pSS, 
ductal and acinar salivary gland epithelial cells display high levels 
of several immunoactive molecules that are known to mediate 
the lymphoid cell homing, antigen presentation and the amplifi ca-
tion of epithelial cell–immune cell interactions. 31 In this scenario, 
the signifi cance of epithelial IL-22 expression in pSS supports the 
important role of the epithelium in the pathogenesis of pSS. 
 IL-22 targets mainly tissue epithelial cells but not immune 
cells. 30 IL-22 mediates signal transduction through a receptor com-
plex consisting of the specifi c IL-22R1 and the common IL-10R2 
subunits. 32 While IL-22R2 is ubiquitously expressed, IL-22R1 is 
restricted on cells of epithelial origins, allowing for IL-22-mediated 
regulation of epithelial cell responses to infective or infl ammatory 
stimuli. 30  33 Interaction of IL-22 with its cognate receptor mainly 
 Figure 5  FACS analysis of NKp44 + NK cells in salivary glands with pSS. Freshly isolated SGMCs from six patients with pSS and six patients with 
nSS were stained with anti-CD3-APC, CD56-PerCP-Cy5.5, NKp-44-PE and IL-22-FITC and analysed by fl ow cytometry. Percentages of NK cells among 
SGMCs of pSS and nSS (A). Percentages of NKp44 + cells in SGMCs of pSS and nSS (B). Correlation of percentages of NKp44 + NK cells with focus 
scores (C). Percentages of NKp44 + NK cells evaluated by FACS analysis were correlated with the focus scores of minor salivary glands of pSS. The 
r=0.88 and p=0.0022 values were determined with Pearson’s correlation coeffi cient. Representative dot plot (left panel) of IL-22 versus NKp44 and 
percentages (right panel) of IL-22-producing NKp44 + NK cells in SGMCs of pSS and nSS (D). Representative immunostainings for NKp44 in patients 
with nSS (E) compared with patients with pSS (F). (E,F) Original magnifi cation, 400×. FACS, fl uorescence-activated cell sorting; IL, interleukin; NK, 
natural killer; nSS, non-specifi c chronic sialoadenitis; pSS, primary Sjögren’s syndrome; SGMC, salivary gland mononuclear cell. 
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results in tyrosine phosphorylation of STAT3. 14 In our study, we 
observed signifi cant modulation of STAT3 mRNA levels in patients 
with pSS compared to those with nSS. The immunohistochemi-
cal analysis clearly showed that p-STAT3 protein was strongly 
expressed in periductal mononuclear cells infi ltrating the salivary 
glands of all patients with pSS. Since the p-STAT3 expression in 
mononuclear cells is mainly induced by IL-6, IL-21 and IL-23, this 
pattern of positivity could be related to the signalling of the afore-
mentioned cytokines. 14 In addition to mononuclear cells, endothe-
lial cells as well as ductal and acinar epithelial cells appeared to 
represent a major source of p-STAT3. The detection of p-STAT3 in 
these cells is in accordance with the notion that STAT3 mediates 
IL-22 signalling in endothelial and epithelial cells. 34 
 At mucosal sites, IL-22 is mainly produced by different leucocyte 
subsets, including Th1, Th17 and Th22 cells as well as NKp44 + NK 
cells. 14 Our demonstration that, among the CD4 + T cell subset, 
Th17 cells were the major source of IL-22 in patients with pSS 
highlights the role of this important subset of effector T cells in the 
pathogenesis of pSS. In addition, we found that a mucosal subset 
of NK cells distinct from conventional NK cells (namely, NKp44 + 
NK cells) 26 were expanded and strongly produced IL-22. NKp44 + 
NK cells express RORC, are not cytotoxic and are present in human 
tonsils, human intestinal lamina propria and Peyer’s patches. 26  35 
Interestingly, regulation of the development and immunological 
behaviour of NKp44 + NK cells is dependent on IL-23. 26 NKp44 + 
NK through the production of IL-22 seems to play a prevalent pro-
tective role in intestinal lamina propria. 36 The strong correlation 
of the percentage of NKp44 + NK cells with the degree of salivary 
gland infl ammation suggests a prevalent pro-infl ammatory role in 
pSS. Nevertheless, the high percentage of IL-22-producing NKp44 + 
NK cells could be the result of a tissue-protective response. 
 In summary, this is the fi rst study to demonstrate that IL-22 is 
abundantly expressed in the infl amed salivary glands of patients 
with pSS. We provide, for the fi rst time, evidence that Th17, 
NKp44 and epithelial cells are the major cellular sources of IL-22 
in pSS. This study confi rms and extends previous knowledge on 
the role of TH17 cells in the pathogenesis of pSS and demon-
strates that TH17 cell are capable to induce prevalent tissue pro 
infl ammatory function of IL-22. On the other hand, we demon-
strated that NKp44 + NK cells are expanded and express a higher 
amount of IL-22, suggesting an important role of this mucosa-
associated NK cell subset in the modulation of the immuno-
logical responses occurring in the infl amed salivary glands of 
patients with pSS. Finally, we also demonstrated that IL-22 is 
expressed in the infl amed ductal epithelial cells of patients with 
pSS, highlighting the role of epithelial cells in the pSS pathogen-
esis. Further studies are needed to address the direct functional 
role of IL-22 in the pathogenesis of pSS. 
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